In this episode, David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, provide expert insights on key data presented at SGO 2022 for ovarian, endometrial, and cervical cancers regarding:Results from the prospective phase III PRIME study of an individualized dose for niraparib vs placebo maintenance in newly diagnosed advanced ovarian cancerFinal OS analysis from phase III SOLO-3 evaluating olaparib vs physician’s choice of single-agent nonplatinum chemotherapy in gBRCAm platinum-sensitive relapsed ovarian cancerResults from the phase III SORAYA trial of mirvetuximab soravtansine, an FRα-targeting ADC with a potent tubulin-targeting maytansinoid (DM4) delivered to tumor cells, in patients with platinum-resistant ovarian cancer who had recurrence within 6 months after last platinum dose and had 1-3 prior treatmentsResults from the randomized, double-blind, placebo-controlled phase III trial of selinexor vs placebo as maintenance in patients with stage IV endometrial cancer who had a PR/CR on ≥12 weeks of first-line taxane/carboplatinThe results from a cost-effectiveness analysis for the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancerPresenters:David Scott Miller, MD, FACOG, FACSAmy and Vernon E. Faulconer Distinguished Chair in Medical ScienceDirector and Dallas Foundation Chair in Gynecologic OncologyProfessor of Obstetrics & GynecologyUniversity of Texas Southwestern Medical CenterMedical Director of Gynecologic OncologyChair, Cancer CommitteeParkland Health & Hospital SystemDallas, Texas Angeles Alvarez Secord, MD, MHSc ProfessorDivision of Gynecologic OncologyDepartment of OB/GYNDuke Cancer InstituteDuke University Health SystemDurham, North Carolina Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/38xuRBv